title: [Esophageal lesions associated with diphosphonates].
abstract: BACKGROUND
  Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events.
  
  
  METHODS
  We report on seven patients who developed severe oesophagitis or oesophageal ulceration during treatment with bisphosphonates. They were registered at our endoscopy unit during a 31-month period.
  
  
  RESULTS
  Six of the patients took alendronate (Fosamax) and one etidronate (Didronate). The oesophageal lesions heal on discontinuation of the bisphosphonate. Institution of gastric acid suppression treatment may enhance the healing process.
  
  
  CONCLUSIONS
  In order to minimise the risk of serious side-effects, it is important to give detailed instructions regarding medication and to ensure that the instructions are properly understood. The risk of serious complications can be reduced by early recognition of oesophageal symptoms and appropriate intervention.
authors.affiliation: Medisinsk avdeling Diakonhjemmets sykehus 0319 Oslo.
authors.forename: K O
authors.initials: KO
authors.lastname: Larsen
authors.forename: N
authors.initials: N
authors.lastname: Stray
authors.forename: V
authors.initials: V
authors.lastname: Engh
authors.forename: D
authors.initials: D
authors.lastname: Sandnes
mesh_terms: D000368:Aged; D019386:Alendronate / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D004940:Esophageal Stenosis / Q000139:chemically induced*; D004941:Esophagitis / Q000139:chemically induced*; D004945:Esophagoscopy; D004947:Esophagus / Q000187:drug effects* / Q000473:pathology; D012968:Etidronic Acid / Q000009:adverse effects*; D005260:Female; D006801:Humans
chemical_list: D004164:Diphosphonates; D012968:Etidronic Acid; D019386:Alendronate